The study consists of 6 consecutive groups, and you will be randomly assigned (like a flip of a coin) to receive either a placebo (liquid without the study drug) or the study drug, at a given dose level. Those in the first group receive the study drug at the lowest dose and the dose level will increase in each proceeding group, with the highest dose of the study drug in the last group (group 6).

There is a total of 8 participants per group, 6 of which would receive the study drug and 2 would receive the placebo. You will receive either the study drug or placebo every two weeks for a total of 4 injections. During the study, neither you nor healthcare professionals at the research site will be aware of who receives the study drug or placebo.

Participants may be eligible to participate in extension phase with bi-weekly drug administration (of active drug) for up to Day 379.

Blood samples taken at each visit. Skin biopsies (a small piece of skin) and medical photographs will be taken on 3 occasions during the study.

Compensation may be provided for time and travel. Participation will come at no cost to you.

Drug administered on which days
Study Length
4 total (Days 1, 15, 29, and 43)
Visits take approximately 1 hour to 2 hours each, except for Days 1, 15, 29, and 43 which may take approximately 6 hours to 8 hours
Blood samples taken at each visit and skin biopsies (a small piece of skin) and medical photographs will be taken on 3 occasions during the study
Study Length
3 month
We are recruiting subjects aged 18 to 75 years (inclusive) with plaque psoriasis, to participate in a research study that evaluates the safety of an investigational study drug (XmAb®27564), and how participants with plaque psoriasis react to the investigational study drug when given multiple times. Investigational study drug means it is a drug that has not been approved by the FDA.

There are 0 locations for this study

Rectangle 191

Are you a researcher or representative of a clinical site?

Join our network of clinical sites and be at the forefront of innovation in clinical research.